The 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes recommend that, along with GLP-1RAs, SGLT2 inhibitors are the preferred anti-hyperglycemic therapy for T2DM patients with ASCVD, independent of glycemic control considerations and independent of background metformin use (25). The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.